Molecular biomarkers of lung carcinoma

Frontiers in Bioscience - Elite

Volumn 4 E, Issue 3, 2012, Pages 865-875

  Branica, Bozica Vrabec ^a   Gajovic, Srecko ^b  

^a KBC Zagreb   (Croatia)

^b UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Carcinoma; Lung; Molecular biomarkers; Review

Indexed keywords

APOLIPOPROTEIN A1; BIOLOGICAL MARKER; CA 125 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19; CYTOKERATIN 19 FRAGMENT; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; K RAS PROTEIN; LONG UNTRANSLATED RNA; MICRORNA; MOLECULAR MARKER; PROTEIN P53; SERUM AMYLOID A; TELOMERASE; TUMOR MARKER; UNTRANSLATED RNA; VASCULOTROPIN; DNA;

ARTICLE; CANCER DIAGNOSIS; CARCINOMA IN SITU; CHROMOSOME 10Q; CHROMOSOME 13Q; CHROMOSOME 15Q; CHROMOSOME 17P; CHROMOSOME 19P; CHROMOSOME 1P; CHROMOSOME 3P; CHROMOSOME 4Q; CHROMOSOME 5Q; CHROMOSOME 8P; CHROMOSOME 9P; CHROMOSOME ARM; CHROMOSOME DELETION; CHROMOSOME XP; CHROMOSOME XQ; DNA MICROARRAY; EARLY CANCER; EARLY DIAGNOSIS; ENZYME ACTIVATION; EPIGENETICS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE LOCUS; GENE TARGETING; GENETIC MARKER; HETEROZYGOSITY LOSS; HUMAN; INVASIVE LUNG CARCINOMA; LUNG ADENOCARCINOMA; LUNG ADENOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; METABOLOMICS; NUCLEOTIDE SEQUENCE; PRECANCER; PROTEIN DNA INTERACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL METAPLASIA; TELOMERE SHORTENING; TUMOR SUPPRESSOR GENE; GENETICS; LUNG TUMOR; METABOLISM; POLYMERASE CHAIN REACTION; REVIEW;

DNA, NEOPLASM; HUMANS; LUNG NEOPLASMS; POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84860848387     PISSN: 19450494     EISSN: 19450508     Source Type: Journal    
DOI: None     Document Type: Article

References (127)

1. J.Y. Cho and H.J. Sung: Proteomic Approaches in Lung Cancer Biomarker Development. Expert Rev Proteomics 6, 7-42 (2009)
2. S. Shiono, K. Omoe and A. Endo: K-ras gene mutation in sputum samples containing atypical cells and adenocarcinoma cells in the lung. Carcinogenesis 17, 1683-1686 (1996) (Pubitemid 26280392)
3. S. Aviel-Ronen, F.H. Blackhall, F.A. Shepherd and M.S. Tsao: K-ras mutations in non-small-cell lung carcinoma: a review. Clin Lung Cancer 8, 30-38 (2006) (Pubitemid 44336241)
4. K. Sugio, T. Ishida, H. Yokoyama, T. Inoue, K. Sugimachi and T. Sasazuki: Ras gene mutations as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis. Cancer Res 52, 2903-2906 (1992)
5. S. Rodenhuis and R.J. Slebos: Clinical significance of ras oncogene activation in human lung cancer. Cancer Res 52. Suppl 9, 2665s-2669s (1992)
6. T.C. Allen, P.T. Cagle and H.H. Popper: Basic Concept of Molecular Pathology. Arch Pathol Lab Med (132), 1551-1556 (2008)
7. J. Niklinski, W. Niklinska, L. Chyczewski, H.D. Becker and E. Pluygers: Molecular genetic abnormalities in premalignant lung lesions: biological and clinical implications. Eur J Cancer Prev 10, 213-226 (2001) (Pubitemid 32530365)
8. R. Salgia and A.T. Skarin: Molecular abnormalities in lung cancer. J Clin Oncol 16, 1207-1217 (1998) (Pubitemid 28108759)
9. S. Gazzeri, E. Brambilla, C. Caron de Fromentel, V. Gouyer, D. Moro, P. Perron, F. Berger and C. Brambilla: p53 genetic abnormalities and myc activation in human lung carcinoma. Int J Cancer 58, 24-32 (1994) (Pubitemid 24213965)
10. E. Brambilla, S. Gazzeri, S. Lantuejoul, J.L. Col, D. Moro, A. Negoescu and C. Brambilla: p53 mutant immunophenotype and deregulation of p53 transcription pathway (Bcl2, Bax and Warf1) in precursor bronchial lesions of lung cancer. Clin Cancer Res 4, 1609-1618 (1998) (Pubitemid 28304721)
11. A.J. Levine: p53, the cellular gatekeeper for growth and division. Cell 88, 323-331 (1997) (Pubitemid 27131374)
12. L. Mao, J.S. Lee, J.M. Kurie, Y.H. Fan, S.M. Lippman, J.J. Lee, J.Y. Ro, A. Broxson, R. Yu, R.C. Morice, B.L. Kemp, F.R. Khuri, G.L. Walsh, W.N. Hittelman and W.K. Hong: Clonal genetic alterations in the lungs of current and former smokers. J Natl Cancer Inst 89, 857-862 (1997) (Pubitemid 27268450)
13. I.I.Wistuba, C. Behrens, S. Milchgrub, D. Bryant, J. Hung, J.D. Minna and A.F. Gazdar: Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma. Oncogene 18, 643-650 (1999) (Pubitemid 29080321)
14. L. Girard, S. Zochbauer-Muller, A.K. Virmani, A.F. Gazdar and J.D. Minna: Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non small cell lung cancer, and loci clustering. Cancer Res 60, 4894-4906 (2000)
15. M.T. Shiseki, J. Kohno, J. Adachi, T. Ozaki, T. Otsuka, H. Mizoguchi, M Noguchi, S Hirohashi and J. Yokota: Comparative allelotype of early and advanced stage nonsmall cell lung carcinomas. Genes Chromosomes Cancer 17, 71-77 (1996) (Pubitemid 26395524)
16. R.C. Tseng, J.W. Chang, F.J. Hsien, Y.H. Chang, C.F. Hsiao, J.T. Chen, C.Y. Chen, Y.S. Jou and Y.C. Wang: Genomewide loss of heterozygosity and its clinical associations in non small cell lung cancer. Int J Cancer 117, 241-247 (2005)
17. C.A. Powell, S. Klares, G. O'Connor and J.S. Brody: Loss of heterozygosity in epithelial cells obtained by bronchial brushing: clinical utility in lung cancer. Clin Cancer Res 5, 2025-2034 (1999) (Pubitemid 29399254)
18. C.A. Powell, R. Bueno, A.C. Borczuk, C.F. Caracta, W.G. Richards, D.J. Sugarbaker and J.S. Brody: Patterns of allelic loss differ in lung adenocarcinomas of smokers and nonsmokers. Lung Cancer 39, 23-29 (2003) (Pubitemid 36020291)
19. H. Pan, J. Califano, J.F. Ponte, A.L. Russo, K. Cheng, A. Thiagalingam, P. Nemani, D. Sidransky and S. Thiagalingam: Loss of heterozygosity patterns provide fingerprints for genetic heterogeneity in multistep cancer progression of tobacco smoke-induced non-small cell lung cancer. Cancer Res 65, 1664-1669 (2005) (Pubitemid 40478590)
20. R.L. De Menezes Duarte and M.E. Machado Paschoal. Molecular markers in lung cancer: prognostic role and relationship to smoking. J Bras Pneumol 32, 56-65 (2005)
21. A.K. Meeker, J.L. Hicks, C. Iacobuzio-Donahue, E.A. Montgomery, W.H. Westra, T.Y. Chan, B.M. Ronnett and A.M. De Marzo: Telomere length abnormalities occur early in the initiation of epithelial carcinognesis. Clin Cancer Res 10, 3317-3326 (2004) (Pubitemid 38685436)
22. J.N. O'Sullivan, J.C. Finley, R.A. Risques, W.T. Shen, K.A. Gollahon, A. H. Moskovitz, S. Gryaznov, C.B. Harley and P.S. Rabinovitch: Telomere length assessment in tissue sections by quntative FISH :image analysis algotithms. Cytometry A 58, 120-131 (2004) (Pubitemid 38509173)
23. G.T. Chung, V. Sundaresan, P. Hasleton, R. Rudd, R. Taylor and P.H. Rabbits: Sequential molecular genetic changes in lung cancer development. Oncogene 11, 2591-2598 (1995) (Pubitemid 26023827)
24. S.A. Belinsky, K.J. Nikula, W.A. Palmisano, R. Michels, G. Saccomanno, E. Gabrielson, S.B. Baylin and J.G. Herman. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci U.S.A. 95,11891-1186 (1998)
25. L. Chaussade, B. Eymin, E. Brambilla and S. Gazzeri: Expression of p15 and p15.5 products in neuroendocrine lung tumours:relationship with p15(INK4b) methylation status. Oncogene 20,6587-6596 (2001) (Pubitemid 32980285)
26. M. Esteller, M. Sanchez-Cespedes, R. Rosell, D. Sidransky, S.B. Baylin and J.G. Herman: Detection of aberrant promoter hypermethylation of tumor suppresor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 59, 67-70 (1999) (Pubitemid 29062958)
27. E. Kurakawa, T. Shimamoto, K. Utsumi, T. Hirano, H. Kato and K. Ohyashiki: Hypermethylation of p16(INK4a) and p15(INK4b) genes in non-small cell lung cancer. Int J Oncol 19, 277-281 (2001)
28. W.A. Palmisano, K.K. Divine, G. Saccomanno, F.D. Gilliland, S.B. Baylin, J.G. Herman and S.A. Belinsky. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 60, 5954-5958 (2000)
29. A.K. Virmani, A. Rathi, S. Zochbauer-Muller, N. Sacchi, Y. Fukuyama, D. Bryant, A. Maitra, S. Heda, K.M. Fong, F. Thunnissen, J.D. Minna and A.F. Gazdar: Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas. J Natl Cancer Inst 92, 1303-1307 (2000) (Pubitemid 30660589)
30. S. Zochbauer-Muller, K.M. Fong, A.K. Virmani, J. Geradts, A.F. Gazdar and J.D. Minna: Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res 61, 249-255 (2001) (Pubitemid 32095725)
31. S. Belinsky: Gene-promoter hypermethylation as a biomarker in lung cancer. Nat Rev Cancer 4, 707-717 (2004) (Pubitemid 39215069)
32. X. Xue, Y.M. Zhu and P.J. Woll: Circulating DNA and lung cancer. Ann N Y Acad Sci 1075, 154-164 (2006) (Pubitemid 44532779)
33. H. Usadel, J. Brabender, K.D. Danenberg, C. Jeronimo, S. Harden, J. Engles, P.V. Danenberg, S. Yang and D. Sidransky: Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum and plasma DNA of patients with lung cancer. Cancer Res 62, 371-375 (2002) (Pubitemid 34106406)
34. J.L. Ramirez, C. Sarries, P.L. De Castro, B. Roig, C. Queralta, D. Escuin, I. De Aguirre, J.M. Sanchez, J.L. Manzano, M. Margeli, J.J. Sanchez, J. Astudillo, M. Taron and R. Rosell: Methylation patterns and K-ras mutations in tumor and paired serum of resected nonsmall cell lung cancer patients. Cancer Lett 193, 207-216 (2003) (Pubitemid 36428904)
35. M. Esteller, M. Sanchez-Cespedes, R. Rosell, D. Sidransky, S.B. Baylin and J.G. Herman: Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from nonsmall cell lung cancer patients. Cancer Res 59, 67-70 (1999) (Pubitemid 29062958)
36. S.A. Belinsky, D.M. Klinge, J.D. Dekker, M.W. Smith, T.J. Bocklage, F.D. Gilliland, R.E. Crowell, D.D. Karp, C.A. Stidley and M.A. Picchi: Gene promoter methylation in plasma and sputum increases with lung cancer risk. Clin Cancer Res 11, 6505-6511 (2005) (Pubitemid 41338988)
37. V.N. Senchenko, J. Liu, W. Loginov, I. Bazov, D. Angeloni, Y. Seryogin, V. Ermilova, T. Kazubskaya, R. Garkavtseva, V.I. Zabarovska, V.I. Kashuba, L.L. Kisselev, J.D. Minna, M.I. Lerman, G. Klein, E.A. Braga and E.R. Zabarovsky: Discovery of frequent homozygous deletions in chromosome 3p21.3 LUCA and AP20 regions in renal, lung and breast carcinomas. Oncogene 23, 5719-5728 (2004) (Pubitemid 39093017)
38. J.S. Wiest, W.A. Franklin, H. Drabkin, R. Gemmill, D. Sidransky and M.W. Anderson: Genetic markers for early detection of lung cancer and outcome measures for response to chemoprevention. J Cell Biochem Suppl 28-29, 64-73 (1997) (Pubitemid 28246629)
39. E.R. Zabarovsky, M.I. Lerman and J.D. Minna: Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers. Oncogene 21, 6915-6935 (2002) (Pubitemid 35221938)
40. X. Xue, Y.M. Zhu and P.J. Woll: Circulating DNA and lung cancer. Ann N Y Acad Sci 1075, 154-164 (2006) (Pubitemid 44532779)
41. J.A. Ludwig and J.N. Weinstein: Biomarkers in Cancer Staging, Prognosis and Treatment Selection. Nat Rev Cancer 5, 845-856 (2005) (Pubitemid 41746029)
42. M. Galasso, M. Elena Sana and S. Volinia: Non-coding RNAs: a key to future personalized molecular therapy? Genome Med 2, 12 (2010)
43. J. Liao, L. Yu, Y. Mei, M. Guarnera, J. Shen, R. Ruiyun, Z. Liu and F. Jiang: Small nucleolar RNA signatures as biomarkers for non-small-cell lung cancer. Molecular Cancer 9, 198 (2010)
44. V. Ambros: MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing. Cell 6, 673-676 (2003) (Pubitemid 36724931)
45. R. Gillet and B. Felden: Emerging views on tmRNAmediated protein tagging and ribosome rescue. Mol Microbiol 4, 879-885 (2001) (Pubitemid 33078373)
46. B.E. Jady and T. Kiss: A small nucleolar guide RNA functions both in 2'-O-ribose methylation and pseudouridylation of the U5 spliceosomal RNA. EMBO J 20, 541-551 (2001) (Pubitemid 32126989)
47. C.L. Bartels and G.J. Tsongalis: MicroRNAs: novel biomarkers for human cancer. Clin Chem 55, 623-631 (2009)
48. G.A. Calin and C.M. Croce: MicroRNA signaturs in human cancers. Nat Rev Cancer 11, 857-866 (2006)
49. J. Lu, G. Getz, E.A. Miska, E. Alvarez-Saavedra, J. Lamb, D. Peck, A. Sweet-Cordero, B.L. Ebert, R.H. Mak, A.A. Ferrando, J.R. Downing, T. Jacks, H.R. Horvitz and T.R. Golub: MicroRNA expression profiles classify human cancers. Nature 435, 834-838 (2005) (Pubitemid 40839735)
50. D.R. Hurst, M.D. Edmonds and D.R. Welch: Metastamir. The field of metastasis-regulatory microRNA is spreading. Cancer Res 69, 7495-7498 (2009)
51. S.K. Shenouda and S.K. Alahari: MicroRNA function in cancer: oncogene or a tumor suppressor? Cancer Metastasis Rev 28, 369-378 (2009)
52. A. Mishra and M. Verma: Cancer Biomarkers. Are We Ready for the Prime Time? Cancer 2, 190-208 (2010)
53. S. Srivastava, M. Verma and R. Gopal-Srivastava: Proteomic maps of the cancer-associated infectious agents. J Proteome Res 4, 1171-1180 (2005) (Pubitemid 41208675)
54. R. Ravichandran, G.B. Vasquez, S. Srivastava, M. Verma, E. Petricoin, J. Lubell, R.D. Sriram, P.E. Barker and G.L. Gilliland: Data Standards for Proteomics: Mitochondrial two-dimensional Polyacrylamide Gel Electrophoresis Data as a Model System. Mitochondrion 3, 327-336 (2004) (Pubitemid 38515399)
55. H.J. Sung and J.Y. Cho: Biomarkers for the lung cancer diagnosis and their advances in proteomics. BMB reports 41, 615-625 (2008)
56. T. Okano, T. Kondo, K. Fujii, T. Nishimura, T. Takano, Y. Ohe, K.Tsuta, Y. Matsuno, A. Gemma, H. Kato, S. Kudoh and S. Hirohashi: Proteomic signature corresponding to the response to gefitinib Iressa, ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor in lung adenocarcinoma. Clin Cancer Res 13, 799-805 (2007) (Pubitemid 46340352)
57. T. Hida, S. Ogawa, J.C. Park, J.Y. Park, J. Shimizu, Y. Horio and K. Yoshida: Gefitinib for the treatment of nonsmall-cell lung cancer. Expert Rev Anticancer Ther 9, 17-35 (2009)
58. S.P. Gygi, G.L. Corthals, Y. Zhang, Y. Rochon and R. Aebrsold: Evaluation of two-dimensional gel electrophoresis-based proteome analysis technology. Proc Natl Acad Sci USA 97, 9390-9395 (2000) (Pubitemid 30650785)
59. K.L. Abbott, A.V. Nairn, E.M. Hall, M.B. Horton, J.F. McDonald, K.W. Moremen, D.M. Dinulescu and M. Pierce: Focused glycomic analysis of the N-linked glycan biosynthetic pathway in ovarian cancer. Proteomics 8, 3210-3220 (2008)
60. T.F. Orntoft and E.M. Vestergaard: Clinical aspects of altered glycosylation of glycoproteins in cancer. Electrophoresis 20, 362-371 (1999) (Pubitemid 29125024)
61. R. Saldova, M.R. Wormald, R.A. Dwek and P.M. Rudd: Glycosylation changes on serum glycoproteins in ovarian cancer may contribute to disease pathogenesis. Dis Markers 25, 219-232 (2008)
62. I.I. Wistuba, C. Behrens, S. Milchgrub, D. Bryant, J. Hung, J.D. Minna and A.F. Gazdar: Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma. Oncogene 18, 643-650 (1999) (Pubitemid 29080321)
63. I.I. Wistuba, S. Lam, C. Behrens, K. A.K. Virmani, K.M. Fong, J. LeRiche, J.M. Samet, S. Srivastava, J.D. Minna and A.F. Gazdar: Molecular damage in the bronchial epitehelium of current and former smokers. J Natl Cancer Inst 89, 1366-1373 (1997) (Pubitemid 27418028)
64. I.I. Wistuba, C. Behrens, A.K. Virmani, G. Mele, S. Milchgrub, L. Girard, J.W. Fondon III, H.R. Garner, B. McKay, F. Latif, M.I. Lerman, S. Lam, A.F. Gazdar and J.D. Minna: High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints. Cancer Res 60, 1949-1960 (2000) (Pubitemid 30207657)
65. V. Sundaresan, P. Ganly, P. Hasleton, R. Rudd, G. Sinha, N.M. Bleehen and P. Rabbitts: p53 and chromosome 3 abnormalities, characteristic of malignant lung tumours are detectable in preinvasive lesions of the bronchus. Oncogene 7, 1989-1997 (1992)
66. G. Sozzi, M. Miozzo, R. Donghi, S. Pilotti, C.T. Cariani, U. Pastorino, G. Della Porta and M.A. Pierotti: Deletions of 17p and p53 mutations in preneoplastic lesions of the lung. Cancer Res 52, 6079-6082 (1992)
67. S.A. Belinsky, W.A. Palmisano, F.D. Gilliland, L.A. Crooks, K.K. Divine, S.A. Winters, M.J. Grimes, H.J. Harms, C.S. Tellez, T.M. Smith, P.P. Moots, J.F. Lechner, C.A. Stidley and R.E. Crowell: Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res 62, 2370-2377 (2002) (Pubitemid 34411720)
68. A. Lamy A, R. Sesboue, J. Bourguignon, B. Dautreaux, J. Metayer and T. Frebourg: Aberrant methylation of the CDKN2a/p16INK4a gene promoter region in preinvasive bronchial lesions: a prospective study in high-risk patients without invasive cancer. Int J Cancer 100, 189-193 (2002) (Pubitemid 34666193)
69. W.H. Westra, R.J. Slebos, G.J. Offerhaus, S. N. Goodman, S.G. Evers, T.W. Kensler, F.B. Askin, S. Rodenhuis and R. H. Hruban: K-ras oncogene activation in lung adenocarcinomas from former smokers: evidence that K-ras mutations are an early and irreversible event in the development of adenocarcinoma of the lung. Cancer 72, 432-438 (1993) (Pubitemid 23193449)
70. H. Sakamoto, J. Shimizu, Y. Horio, R. Ueda, T. Takahashi, T. Mitsudomi and Y. Yatabe: Disproportionate representation of KRAS gene mutation in atypical adenomatous hyperplasia, but even distribution of EGFR gene mutation from preinvasive to invasive adenocarcinomas. J Pathol 212, 287-294 (2007) (Pubitemid 47010062)
71. K.M. Kerr, F.A. Carey, G. King and D. Lamb: Atypical alveolar hyperplasia: relationship with pulmonary adenocarcinoma, p53 and c-erbB-2 expression. J Pathol 174, 249-256 (1994)
72. R.J. Slebos, I.O. Baas, M.J. Clement, G.J. Offerhaus, F.B. Askin, R.H. Hruban and W.H. Westra: p53 alterations in atypical alveolar hyperplasia of the human lung. Hum Pathol 29, 801-808 (1998) (Pubitemid 28375985)
73. G. Giaccone, R.M. Gallegos, T. Le Chevalier, N. Thatcher, E. Smith, J.A. Rodriguez, P. Janne, D. Oulid-Aissa and J. Soria: Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. Clin Cancer Res 12, 6049-6055 (2006) (Pubitemid 44703768)
74. E. Massarelli, M. Varella-Garcia, X. Tang, A.C. Xavier, N.C. Ozburn, D.D. Liu, B.N. Bekele, R.S. Herbst and I.I. Wistuba: KRAS mutation in an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 13, 2890-2896 (2007) (Pubitemid 46849563)
75. J.G. Paez , P.A. Janne, J.C. Lee, S. Tracy, H. Greulich, S. Gabriel, P. Herman, F.J. Kaye, N. Lindeman, T.J. Boggon, K. Naoki, H. Sasaki, Y. Fujii, M.J. Eck, W.R. Sellers, B.E. Johnson and M. Meyerson: EGFR mutations in lung cancer:correlation with clinical response to gefitinib thrapy. Science 304, 1497-1500 (2004) (Pubitemid 38720929)
76. W. Pao, T.Y. Wang, G.J. Riely, V. A. Miller, Q. Pan, M. Ladanyi, M.F. Zakowski, R.T. Heelan, M.G. Kris and H.E. Varmus: KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PloS Med 21, e17 (2005)
77. S.E. Monaco, M.N. Nikiforova, K. Cieply, L.A. Teot , W.E. Khalbuss and S. Dacic: A comparison of EGFR and KRAS status in primary lung carcinoma and matched metastases. Hum Pathol 41, 94-102 (2010)
78. P. Ulivi, D. Calistri, W. Zoli and D. Amadori: Predictive molecular markers for EGFR-TKI non-small cell lung cancer patients: new insights and critical aspects. J Nucl Acid Invest 1, e10 (2010)
79. G. Bocci, S. Man, S.K. Green, G. Francia, J.M.L. Ebos, J.M. du Manoir, A. Weinerman, U. Emmenegger, L.Ma, P. Thorpe, A. Dawidoff, J. Huber, D.J. Hicklin and R.S. Kerbel: Increased Plasma Vascular Endothelial Growth Factor (VEGF) as a Surrogate Marker for Optimal Therapeutic Dosing of VEGF Receptor-2 Monoclonal Antibodies. Cancer Res 64, 6616-6625 (2004) (Pubitemid 39297922)
80. A.F. Gazdar and J.D. Minna: Molecular detection of early lung cancer. J Natl Cancer Inst 91, 299-301 (1999) (Pubitemid 29102328)
81. S.M. Hanash, S.J. Pitteri and V.M. Faca: Mining the plasma proteome for cancer biomarkers. Nature 452, 571-579 (2008) (Pubitemid 351483371)
82. F. Barlesi, C. Tchouhadjian, C. Doddoli, J.P. Torre, P. Astoul and J.P. Kleisbauer: CYFRA21-1 level predicts survival in non-small-cell lung cancer patients receiving gefitinib as third-linr therapy. Br J Cancer 92, 13-14 (2005) (Pubitemid 40188428)
83. S. Garg, U. Handa, H. Monah and A.K. Janmeja: Comparative analysis of various cytohisological techniques in diagnosis of lung diseases. Diagn Cytopathol 35, 26-31 (2007) (Pubitemid 46095110)
84. A. Kalikaki, A. Koutsopoulos, M. Trypaki, J. Souglakos, E. Stathopoulos, V. Georgoulias, D. Mavroudis and A. Voutsina: Comparison of EGFR and KRAS gene status between primary tumours and coresponding metastases in NSCLC. Br J Cancer 99, 323-329 (2008)
85. C.H. Gow, Y.L. Chang, Y.C. Hsu, M.F. Tsai, C.T. Wu, C.J. Yu, C.H. Yang, Y.C. Lee, P.C. Yang and J.Y. Shih: Comparison of epidermal growth factor receptor mutations between primary and coresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer. Ann Oncol 20, 696-702 (2009)
86. A. Horiike, H. Kimura, K. Nishio, F. Ohyanagi, Y. Satoh, S. Okumura, Y. Ishikawa, K. Nakagawa, T. Horai and M. Nishio: Detection of epidermal growth factor receptor mutation in transbronchial needle aspirates on non-small cell lung cancer. Chest 131, 1628-1634 (2007) (Pubitemid 46981613)
87. J.H. Smouse, E.S. Cibas, P.A. Jänne, V.A. Joshi, K.H. Zou and N.I. Lindeman: EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer. Cancer Cytopathol 117, 67-72 (2009)
88. M.F. Zakowski, S. Hussain, W. Pao, M. Ladanyi, M.S. Ginsberg, R. Heelan, V.A. Miller, V.W. Rusch and M.G. Kris: Morphologic features of adenocarcinoma of the lung predictive of response to the epidermal growth factor receptor kinase inhibitors erlotinib and gefitinib. Arch Pathol Lab Med 133, 470-477 (2009)
89. L. Boldrini, S. Gisfredi, S. Ursino, T. Camacci, E. Baldini, F. Melfi and G. Fontanini: Mutational analysis in cytological specimens of advanced lung adenocarcinoma: a sensitive method for molecular diagnosis. J Thorac Oncol 2, 1086-1090 (2007) (Pubitemid 350307900)
90. C. Bozetti, M. Tiseo, C. Lagranza, R. Nizzoli, A. Guazzi, F. Leonardi, D. Gasparo, E. Spiritelli, M. Rusca, P. Carbognani, M. Majori, V. Franciosi, G. Rindi and A. Ardizzoni: Comparison between epidermal growth factor receptor (EGFR) gene expression in primary non-small cell lung cancer (NSCLC) and in fine-needle aspirates from metastatic sites. J Thor Oncol 3, 18-22 (2008)
91. L. Daniele, L. Macri, M. Schena, D. Dongiovanni, L. Bonello, E. Armando, L. Ciuffreda, O. Bertetto, G. Bussolati and A. Sapino: Predicting gefitinib responsiveness in lung cancer by fluorescence in situ hybridization analysis of EGFR and HER2 in biopsy and cytology specimens. Mol Cancer Ther 6, 1223-1229 (2007) (Pubitemid 46711985)
92. E.X. Wei, A.A. Anga, S.S. Martin, J.G. Jackson, M.L. Nordberg, G.A. Herrera and E.A. Turbat-Herrera: EGFR expression as an acillary tool for diagnosing lung cancer in cytology specimns. Mod Pathol 20, 905-913 (2007) (Pubitemid 47267831)
93. L.A. Brown and D. Huntsman: Fluorescent in situ hybridization on tissue microarrays: challenges and solutions. J Mol Histol 38, 151-157 (2007) (Pubitemid 46659334)
94. K.C. Halling and B.R. Kipp: Fluorescence in situ hybridization in diagnostic cytology. Hum Pathol 38, 1137-1144 (2007) (Pubitemid 47058172)
95. Z. Theodosiou, I.N. Kasmpalidis, G. Livanos, M. Zervakis, I. Pitas and K. Lyroudiaz: Automated analysis of FISH and immunohistochemistry images: a review. Cytometry 71A, 439-450 (2007) (Pubitemid 47036034)
96. B.J. Dave and W.G. Sanger: Role of cytogenetics and molecular cytogenetics in the diagnosis of genetic imbalances. Semin Pediatr Neurol 14, 2-6 (2007)
97. S. Krishnamurthy: Applications of molecular techniques to fine-needle aspiration biopsy. Cancer (Cancer Cytopathol) 111, 106-122 (2007) (Pubitemid 46655642)
98. J. Bayani and J.A. Squire: Application and interpretation of FISH in biomarker studies. Cancer Lett 249, 97-109 (2007) (Pubitemid 46437281)
99. F.C. Tenover: Rapid detection and identification of bacterial pathogens using novel molecular technologies: infection control and beyond. Clin Infect Dis 44, 418-423 (2006) (Pubitemid 46147627)
100. I. Raad, H. Hanna, A. Huaringa, D. Sumoza, R. Hachem and M. Albitar: Diagnosis of invasive pulmonary aspergillosis using polymerase chain reaction-based detection of aspergillus in BAL. Chest 121, 1171-1176 (2002) (Pubitemid 34280439)
101. L.M. Nogee, A.E. Dunbar III, S.E. Wert, F. Askin, A. Hamvas and J.A. Whitsett: A mutation in the surfactant protein C gene associated with familial interstitial lung disease. N Engl J Med 344, 573-579 (2001) (Pubitemid 32167871)
102. J.L. Lordan, F. Bucchieri, A. Richter, A. Konstantinidis, J.W. Halloway, M. Thornber, S.M. Puddicombe, D. Buchanan, S.J. Wilson, R. Djukanovic, S.T. Holgate and D.E. Davies: Cooperative effects of Th2 cytokines and allergen on normal and asthmatic bronchial epithelial cells. J Immunol 169, 407-414 (2002) (Pubitemid 34686162)
103. W.H. Westra, I.O. Baas, R.H. Hruban, F.B. Askin, K. Wilson, G.J.A. Offerhaus and R.J.C. Slebos: K-ras oncogene activation in atypical alveolar hyperplasia of the human lung. Cancer Res 56, 2224-2228 (1996) (Pubitemid 26119929)
104. D. Pulte, E. Li, B.K. Crawford, E. Newman, A. Alexander, D.C. Mustalish and D.R. Jacobson: Sentinel lymph node mapping and molecular staging in nonsmall cell lung carcinoma. Cancer 104, 1453-1461 (2005) (Pubitemid 41356160)
105. R.M. Bremnes, R. Sirera and C. Camps: Circulating tumour derived DNA and RNA markers in blood: a tool for early detection, diagnostic and follow-up? Lung Cancer 49, 1-12 (2005) (Pubitemid 40798088)
106. Q. Pan, W. Pao and M. Ladanyi: Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. J Mol Diagn 7, 396-403 (2005) (Pubitemid 41149655)
107. T. Bohlmeyer, T.N. Le, A.L. Shroyer, N. Markham and K.R. Shroyer: Detection of human papillomavirus in squamous cell carcinomas of the lung by polymerase chain reaction. Am J Respir Cell Mol Biol 18, 265-269 (1998) (Pubitemid 128355200)
108. R.P. Valle, C. Chavany, T.A. Zhukov and M. Jendoubi: New approaches for biomarker discovery in lung cancer. Expert Rev Mol Diagn 3, 55-67 (2003) (Pubitemid 36061550)
109. M.S. Tockman: Clinical detection of lung cancer progression markers. J Cell Biochem 25, 177-184 (1996) (Pubitemid 27078329)
110. V.E. Velculescu, L. Zhang, B. Vogelstein and K.W. Kinzler: Serial analysis of gene expression. Science 270, 484-487 (1995)
111. G. Zhou, H. Li, D. DeCamp, S. Chen, H. Shu, Y. Gong, M. Flaig, J.W. Gillespie, N. Hu, P.R. Taylor, M.R. Emmert-Buck, L.A. Liotta, E.F. Petricoin and Y. Zhao: 2D differential in-gel electrophoresis for the identification of esophageal scans cell cancer-specific protein markers. Mol Cell Proteomics 1, 117-124 (2002)
112. M. Verma, J. Kagan, S. Sidransky and S. Srivasatava: Proteomic analysis of the cancer cell mitochondria. Nat Rev Cancer 3, 789-795 (2003) (Pubitemid 37328817)
113. P.A. Everly, J. Krijgsveld, B.R. Zetter and S.P. Gaygi: Quantitative cancer proteomics: stable isotope labeling with amino acids in cell culture (SILAC) as a tool for prostate cancer research. Mol Cell Proteomics 3, 729-735 (2004) (Pubitemid 39077003)
114. C.P. Paweletz, L.Charboneau, V.E. Bichsel, N.L. Simone, T. Chen, J.W. Gillespie, M.R. Emmert-Buck, M.J. Roth, E.F. Petricoin III and L.A. Liotta: Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 20, 1981-1989 (2001) (Pubitemid 32458030)
115. T. Sano, C.L. Smith and C.R. Cantor: Immuno-PCR: very sensitive antigen detection by means of specific antibody-DNA conjugates. Science 258, 120-122 (1992)
116. J.M. Nam, C.S. Thaxton and C.A. Mirkin :Nanoparticle-based bio-bar codes for the ultrasensitive detection of proteins. Science 301, 1884-1886 (2003) (Pubitemid 37221389)
117. S.F. Service. American Chemical Society Meeting. Tiny transistors scout for cancer. Science 300, 242-243 (2003)
118. C. Seydel: Quantum dots get wet. Science 300, 80-81 (2003) (Pubitemid 36423030)
119. Y. Misonou, K.Shida, H. Korekane, Y. Seki, S. Noura, M. Ohue and Y. Miyamoto: Comprehensive clinicoglycomic study of 16 colorectal cancer specimens: elucidation of aberrant glycosylation and its mechanistic causes in colorectal cancer cells. J Proteome Res 8, 2990-3005 (2009)
120. A.S. Powlesland, P.G. Hitchen, S. Parry, S.A. Graham, M.M. Barrio, M.T. Elola, J. Mordoh, A. Dell, K. Drickamer and M.E. Taylor: Targeted glycoproteomic identification of cancer cell glycosylation. Glycobiology 19, 899-909 (2009)
121. W. Cao, M. Hashibe, J.Y. Rao, H. Morgenstern and Z.F. Zhang: Comparison of methods for DNA extraction from paraffin-embedded tissues and buccal cells. Cancer Detect Prev 27, 397-404 (2003) (Pubitemid 37365555)
122. C. Mulot, I. Stucker, J. Clavel, P. Beaune and M.A. Loriot: Collection of human genomic DNA from buccal cells for genetics studies: comparison between cytobrush, mouthwash and treated card. J Biomed Biotechnol 3, 291-296 (2005) (Pubitemid 43120937)
123. B. Vrabec Branica, D. Mitrecic, S. Grgic, S. Smojver Jezek, N. Chalfe and S. Gajovic: PCR Quality DNA Isolation from Human Bronchial Aspirates and Buccal and Eyelid Swabs by a Simple Procedure Based on Alkaline Lyses. Genet Test and Mol Biom 13, 799-802 (2009)
124. L. Rudbeck and J. Dissing: Rapid, simple alkaline extraction of human genomic DNA from whole blood, buccal epithelial cells, semen and forensic stains for PCR. Biotechniques 25, 588-592 (1998) (Pubitemid 28465687)
125. M. Meldegaard, P.J. Bollen and B. Finsen: Noninvasive method for sampling and extraction of mouse DNA for PCR. Lab Anim 25, 588-592 (2004)
126. D. Mitrecic, S. Mavric, B. Vrabec Branica and S. Gajovic: Mice genotyping using buccal swab samples-An improved mrthod. Biochem Genet 46, 105-112 (2008)
127. B. Vrabec Branica, S. Smojver-Jezek, Z. Juros, S. Grgic, N. Srpak, D. Mitrecic and S. Gajovic: Detection of Human Papillomaviruses Type 16,18 and 33 in Bronchial Aspirates of Lung Carcinoma Patients by Polymerase Chain Reaction: A Study of 84 Cases in Croatia. Coll Antropol 34, 159-162 (2010)